| Literature DB >> 31395834 |
Seham S El-Hawary1, Ahmed M Sayed2, Rabab Mohammed3, Hossam M Hassan3, Mostafa E Rateb3,4,5, Elham Amin3, Tarek A Mohammed6, Mohamed El-Mesery7,8, Abdullatif Bin Muhsinah9, Abdulrhman Alsayari9, Harald Wajant7, Mohamed A Anany10,11, Usama Ramadan Abdelmohsen12.
Abstract
In the present study, LC-HRESIMS-assisted dereplication along with bioactivity-guided isolation led to targeting two brominated oxindole alkaloids (compounds 1 and 2) which probably play a key role in the previously reported antibacterial, antibiofilm, and cytotoxicity of Callyspongia siphonella crude extracts. Both metabolites showed potent antibacterial activity against Gram-positive bacteria, Staphylococcus aureus (minimum inhibitory concentration (MIC) = 8 and 4 µg/mL) and Bacillus subtilis (MIC = 16 and 4 µg/mL), respectively. Furthermore, they displayed moderate biofilm inhibitory activity in Pseudomonas aeruginosa (49.32% and 41.76% inhibition, respectively), and moderate in vitro antitrypanosomal activity (13.47 and 10.27 µM, respectively). In addition, they revealed a strong cytotoxic effect toward different human cancer cell lines, supposedly through induction of necrosis. This study sheds light on the possible role of these metabolites (compounds 1 and 2) in keeping fouling organisms away from the sponge outer surface, and the possible applications of these defensive molecules in the development of new anti-infective agents.Entities:
Keywords: Callyspongia siphonella; LC-HRESIMS; antibacterial; antibiofilm; anticancer; antitrypanosomal; metabolomic profiling; oxindole alkaloids; tisindoline
Mesh:
Substances:
Year: 2019 PMID: 31395834 PMCID: PMC6723499 DOI: 10.3390/md17080465
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Identified compounds by dereplication with LC-HRESIMS.
Dereplication of the metabolites previously identified from Callyspongia siphonella.
| NP | Compound | RT (min) | [M + H]+ | Calculated Mass | Chemical Formula |
|---|---|---|---|---|---|
|
| Compound | 3.21 | 442.0552 | 442.0555 | C24H17N3OBr |
|
| Compound | 3.32 | 442.552 | 442.0555 | C24H17N3OBr |
|
| Sipholenol A | 5.96 | 477.3941 | 477.3944 | C30H53O4 |
|
| Sipholenone A | 6.41 | 475.3785 | 475.3787 | C30H51O4 |
|
| Callysterol | 7.12 | 401.381 | 401.3783 | C28H49O |
|
| Cholestenone | 7.38 | 385.3472 | 385.347 | C27H45O |
|
| 5α-cholestanone | 7.41 | 387.3625 | 387.3627 | C27H47O |
|
| Stigmasterone | 7.49 | 411.3634 | 411.3637 | C29H47O |
|
| stigmasta-4,22-dien-3,6-dione | 6.95 | 425.345 | 425.342 | C29H45O2 |
|
| Petroselenic acid | 8.91 | 283.2634 | 283.2637 | C18H35O2 |
|
| Callyspongidipeptide A | 2.26 | 227.139 | 227.1396 | C11H19N2O3 |
|
| Callysponginol sulfate A | 2.6 | 459.2783 | 459.278 | C24H43O6S |
|
| 2.7 | 190.0501 | 190.0504 | C10H8NO3 | |
|
| Trisindoline | 2.86 | 364.1456 | 364.145 | C24H18N3O |
|
| 1,2,3,4-tetrahydro-1- methyl-β-carboline-3-carboxylic acid | 2.99 | 231.1133 | 231.1134 | C13H15N2O2 |
|
| Callystatin A | 3.83 | 457.3325 | 457.3318 | C29H45O4 |
|
| Hydroxydihydrobovolide | 3.88 | 199.1339 | 199.1334 | C11H19O3 |
|
| Callyspongidic acid | 3.95 | 395.2429 | 395.2434 | C22H35O6 |
|
| Callyspongendiol | 4.51 | 437.3413 | 437.3420 | C30H45O2 |
|
| 15,16-epoxy-22-hydroxysipholen-one A | 5.18 | 507.3676 | 507.3686 | C30H51O6 |
|
| Sipholenoside B | 5.34 | 623.452 | 623.4523 | C36H63O8 |
|
| Sipholenol G | 5.39 | 493.3889 | 493.3893 | C30H53O5 |
|
| Sipholenoside A | 5.63 | 621.4368 | 621.4366 | C36H61O8 |
|
| Sipholenone C | 6.26 | 489.3562 | 489.3580 | C30H49O5 |
Isolated in the present study as a new natural product. Isolated in the present study for the first time from C. siphonella. Previously reported from C. siphonella and confirmed by isolation.
1H- (400 MHz) and 13C-NMR (100 MHz) for compounds 1 and 2 in DMSO-d6.
| Compound 1 | Compound 2 | |||
|---|---|---|---|---|
| Position | ||||
|
| 10.77 (br s, 1H) | - | 10.75, (br s, 1H) | - |
|
| - | 178.9, C | - | 179, C |
|
| - | 53.2, C | - | 52.7, C |
|
| - | 137.4, C | - | 134.3, C |
|
| 7.30, (s, 1H) | 127.8, CH | 7.16, (d, 8Hz, 1H) | 127.1, CH |
|
| - | 114, C | 7.12, (dd, 2Hz, 8Hz, 1H) | 124.6, CH |
|
| 7.42, (d, 8Hz, 1H) | 131.2, CH | - | 120.7, C |
|
| 6.97, (d, 8Hz, 1H) | 112.2, CH | 7.14, (s, 1H) | 112.8, CH |
|
| - | 141.1, C | - | 143.5, C |
|
| 11.03 (br s, 2H) | - | 11.0, (br s, 1H) | - |
|
| 6.89, (s, 2H) | 124.9, CH | 6.85, (d, 2.5Hz, 2H) | 124.8, CH |
|
| - | 113.6, C | - | 114.0, C |
|
| - | 126, C | - | 126, C |
|
| 7.22, (d, 8Hz, 2H) | 121, CH | 7.2, (d, 8Hz, 2H) | 121, CH |
|
| 6.83, (t, 8Hz, 2H) | 119, CH | 6.81, (t, 8Hz, 2H) | 118.8, CH |
|
| 7.04, (t, 8Hz, 2H) | 121.5, CH | 7.03, (t, 8Hz, 2H) | 121.5, CH |
|
| 7.39, (d, 8Hz, 2H) | 112.2, CH | 7.35, (d, 8Hz, 2H) | 112.1, CH |
|
| - | 137.4, C | - | 137.4, C |
Figure 21H–1H COSY and key HMBC correlations of compounds 1,2.
Inhibition zone diameter (mm) of the ethanol extract and fractions of C. siphonella on different bacterial strains (mean ± standard error (SE).
| Tested Extract |
|
|
|
|
|---|---|---|---|---|
| EtOH Ext | 1.1 ± 0.5 | 1.2 ± 0.2 | - | - |
| Hex | 2.3 ± 0.9 | 1.1 ± 0.4 | - | 1 ± 0.4 |
| EtOAc | 6.6 ± 0.2 | 5.4 ± 0.3 | 1.5 ± 0.7 | - |
| ButOH | - | 0.5 ± 0.2 | - | - |
| Ampicillin | 13.7 ± 0.9 | 12.3 ± 1.2 | 3.9 ± 0.9 | 3.6 ± 0.3 |
| Gentamicin | 9.8± 1.2 | 10.1 ± 1.1 | 15.5 ± 0.1 | 14.8 ± 1.3 |
Ampicillin, gentamicin, extracts, and fractions (20 µg/mL DMSO). EtOH, ethanol extract; Hex, n-hexane fraction; EtOAc, ethyl acetate fraction; ButOH, n-butanol fraction. (-) indicates no growth inhibition found.
Inhibition zone diameter (mm) of 1 and 2 on different bacterial strains (mean ± SE).
| Tested compound |
|
|
|
|
|---|---|---|---|---|
|
| 17.5 ± 0.8 | 18 ± 0.1 | 0.5 ± 0.1 | 1.3 ± 0.3 |
|
| 15 ± 1.1 | 16.4 ± 0.9 | 0.2 ± 0.2 | 1.1 ± 0.7 |
| Amikacin | 23.5 ± 0.8 | 20.2 ± 0.6 | 15.4 ± 0.4 | 16.3 ± 0.9 |
Minimal inhibitory concentration (MIC) (µg/mL) values of 1 and 2.
| Fungal metabolite |
|
|
|
|
|---|---|---|---|---|
|
| 8 | 4 | >256 | 256 |
|
| 16 | 4 | >256 | 256 |
| Ampicillin | 2 | 2 | 4 | 8 |
| Gentamicin | 16 | 8 | 0.5 | 1 |
Antibiofilm activity of 1 and 2 in Pseudomonas aeruginosa PA01.
| Isolated compound | % Inhibition |
|---|---|
|
| 49.32 ± 1.18 |
|
| 41.76 ± 1.33 |
| Azithromycin | 52.62 ±1.23 |
Each compound was tested at concentration of 128 µg/mL (0.5 MIC). Azithromycin was tested at a concentration of 16 µg/mL (0.5 MIC).
Cytotoxic effects of 1 and 2 expressed by half maximal inhibitory concentration (IC50) values.
| Compounds | IC50 (µM) a | ||
|---|---|---|---|
| HT-29 | OVCAR-3 | MM. 1S | |
|
| 8 ± 0.8 | 7 ± 0.3 | 9 ± 0.7 |
|
| 12.5 ± 0.3 | 9 ± 0.6 | 11 ± 0.9 |
a Values are means of three independent experiments. human colon cancer cell line: HT-29; human ovarian cancer cell line: OVCAR-3; multiple myeloma cell line: MM.1S.
Figure 3Cytotoxic effects of compounds 1 and 2 on human colon cancer (HT-29), human ovarian cancer (OVACR-3), and multiple myeloma (MM.1s) cell lines. The cells were stimulated overnight with increasing concentrations of compounds 1 and 2. on the next day, cellular viability was determined by crystal violet staining for HT-29 and OVACR-3, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for MM.1s.
Figure 4Morphological changes of HT-29, OVCAR-3, and MM.1S cells incubated overnight with compound (1) (20 µM) in comparison to untreated cells using an EVOS FL digital microscope.
Figure 5Western blotting analysis of 1 against beclin and caspase 3, the key proteins of autophagy and apoptosis, respectively.